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THE EDITOR
The WT1 gene is expressed in a limited set of tissues during fetal development, consistent with its critical role in early nephrogenesis and in the development of gonads. 1 The gene is also expressed in acute leukemias and in CD34
+ hematopoietic progenitor cells. 2 The expression of this gene is down-regulated during differentiation of hematopoietic cells. 3 These findings suggest that WT1 plays an important role in hematopoiesis and in hematological malignancies. So far, it has been reported that about 10-15% of acute nonlymphoid leukemias had the mutation of the WT1 gene. 4, 5 All of the mutations reported resulted in loss of zinc fingers or were predicted to affect the DNA binding function. All leukemias with WT1 mutations were eventually refractory to treatment, suggesting that the WT1 gene is associated with aggressive disease. 4, 5 Secondary leukemia or therapy-related leukemia is caused by treatment with radiation, alkylating drugs, topoisomerase II inhibitors and other chemotherapeutic agents. The vast majority of secondary leukemias are bilineage or nonlymphoid hematological malignancies with poor prognosis. The molecular mechanism underlying poor prognosis in secondary leukemia remains to be demonstrated. To investigate whether the WT1 gene is associated with secondary leukemia, we examined the WT1 gene for mutations in six cases of secondary leukemias. A single WT1 mutation in exon 7 was found in a patient with acute myeloid leukemia (AML).
Bone marrow samples were obtained from six patients with secondary leukemia. The characteristics of the patients are shown in Table 1 . Mononuclear cells were isolated by centrifugation over Lymphoprep (Nycomed, Oslo, Norway) from bone marrow aspirates. DNA was extracted from the mononuclear cells by proteinase K digestion and phenol extraction. WT1 exons 1 to 10 were analyzed by the single strand conformational polymorphism (SSCP) technique. The primers used were described previously. 2, 6 Prior to PCR, oligonucleotides were radiolabeled with T4 polynucleotide kinase and (␥-32 P) ATP. Each PCR was performed in 25 l reaction mixture containing 50 mM KCl, 10 mM Tris-HCl (pH 8.8), 1.5 mM MgCl 2 , 0.1% Triton-100, 200 M dNTP mixture, 1 unit Amersham Taq DNA polymerase, 10 pmol of each primer and 100 ng genomic DNA. Thirty cycles of amplification were performed, each consisting of 1 min at 94°C, 1 min at the optionally determined annealing temperature for each oligonucleotide pair and 1 min at 72°C. PCR products were mixed with 50 l of sample buffer containing 95% formamide and boiled for 5 min. Aliquots of 3 l were electrophoresed on 5% nondenaturing polyacrylamide (49:1, acrylamide:bisacrylamide) gels in 1 × TBE buffer at 50 W and 15°C. PCR products were subcloned into a TA cloning vector (pCR; Invitrogen BV, Leek, The Netherlands) and sequenced using a Sequenase PCR sequencing kit (Amersham).
An altered band of PCR in exon 7 was seen in a single sample (Figure 1a) . In addition to the expected band, a smaller-sized PCR product was found from patient 6 with AML (M2). Sequencing revealed that the abnormal band resulted from a 38-bp deletion at codon 300 upstream of the first zinc finger causing a frameshift and the loss of the entire zinc finger region (Figure 1b) . The mutant allele was absent in the normal blood cells taken from the patient in complete remission, indicating that this was a somatic mutation. This patient had been treated with radiation for cervical squamous cell carcinoma (large cell keratinizing type). Four years after radiotherapy she was diagnosed as AML. No chromosomal aberration was found in this patient. She is now alive 5 years after the diagnosis of the secondary leukemia. No mutation was found in other patients by SSCP.
Patients with secondary leukemia have been shown to have a poor response to treatment and worse prognosis. The chromosome aber- rations which are frequently seen in secondary leukemias are monosomy 5, deletion of chromosome 5, monosomy 7, deletion of chromosome 7 and 11q23 rearrangement. Rearrangement of the MLL gene in the 11q23 locus has been detected in secondary leukemia in patients who have received topoisomerase II inhibitors. The critical genes responsible for the genesis of secondary leukemia mapped to other chromosomal regions are unknown. The p53 gene, which is frequently mutated in human cancers, is rarely mutated in secondary leukemia.
WT1 was originally identified as a tumor suppressor gene whose mutations are found in approximately 10% of Wilms' tumors. A WT1 mutation in leukemia was first found in a secondary leukemia occurring in a WAGR patient with Wilms' tumor, aniridia and mild developmental delay. 7 She was treated by nephrectomy, radiotherapy and chemotherapy with actinomycin D. Subsequent studies revealed that WT1 is mutated in approximately 15% of primary leukemia, mainly in AML. 4, 5 Prompted by these findings, we screened the WT1 gene for mutation in secondary leukemias. We have found a single WT1 mutation in one of six (16.6%) cases of secondary AML, suggesting that WT1 mutation is not preferentially associated with secondary leukemia. WT1 may be equally important in both leukemias.
The WT1 mutation in this study is a 38-bp deletion from codon Val 300 in exon 7. Since an A to G change at a polymorphic site at codon Arg 301 within the deletion does not generate any specific sequences at the breakpoint, the polymorphism is unlikely to have a role in the abnormality found in the patient.
2 High levels of WT1 gene expression are frequently found in acute leukemias. 8 Therefore, it is highly likely that this case expressed the mutant allele, generating a truncated protein without zinc fingers. The loss of the entire zinc finger region would be expected to abolish DNA binding capacity. This case appears to be heterozygous for the WT1 mutation. Although apparent heterozygosity could be caused by contamination with normal blood cells, this is unlikely as the sample contained 80% of leukemic cells. Previous findings that the majority of WT1 mutations in leukemias were heterozygous mutations support the heterozygosity of the mutation in this case. 4, 5 The mutant allele could lead to loss of WT1 function in a dominant-negative manner. 6 According to previous reports, all leukemias with WT1 mutation had poor prognosis. This is the only case with a good response to chemotherapy. The association between WT1 mutation and prognosis merits further investigation. . In addition to a wild-type transcript, a smaller-sized PCR product was found. (b) Sequencing of a subcloned plasmid containing the smaller-sized PCR product. An asterisk at codon 300 indicates the site of a 38 bp deletion in exon 7. This deletion caused a frameshift, which resulted in the loss of entire zinc finger domain.
